stockrow
Saturday 7 November 2026
Export LNAI’s income statement to Excel — free account
Lunai Bioworks Inc.
LNAI Healthcare Biotechnology
Lunai Bioworks Inc.’s revenue for fiscal 2026 (year ended June 2026) was $52,000.00.
- EPS
- +99.0%
- Free cash flow
- −1.65%
Quarter to June 2026, against a year earlier
0.16
0.00
0.00%
Follow LNAI
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | 116.05 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (9.92) | (5.97) | |
P/B ratio |
— | — | 0.00 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 0.00 | 110.63 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (1.57) | (1.98) | |
EV/FCF |
— | — | (1.56) | (1.97) | |
Quick Ratio |
0.03 | 0.02 | 0.16 | 0.09 | |
Current Ratio |
0.04 | 0.03 | 0.19 | 0.11 | |
Net Debt/EBITDA |
0.19 | 0.28 | 2.28 | 0.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 | |
Operating CF/Net income |
(0.48) | 0.60 | 0.40 | 0.92 | |
Capex/Depreciation |
0.00 | (0.02) | 0.00 | 0.00 | |
Interest Coverage |
(27.03) | (15.01) | (13.20) | 15.61 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 76.08% | (198.39%) | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 6,800.48% | 7,080.39% | |
Intangible Assets out of Total Assets |
0.88 | 0.92 | 0.62 | 0.79 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 808.61% | 0.00% | |
Graham Net Nets |
— | — | (1.54) | (1.54) | |
Graham Number |
— | — | 64.82 | 7.87 | |
Earnings Yield |
— | — | (1,873.47%) | (31.35%) | |
Free Cash Flow Yield |
— | — | (51.92%) | (48.34%) | |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.01 | |
Operating CF per Share |
(0.48) | (0.36) | (0.33) | (0.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.48) | (0.37) | (0.33) | (0.55) | |
Cash per Share |
0.22 | 0.17 | 1.01 | 0.51 | |
Shareholders Equity per Share |
(4.63) | (4.62) | (3.06) | (2.69) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(4.63) | (4.62) | (3.06) | (2.69) | |
Free Cash Flow |
(1.35) | (1.07) | (1.03) | (1.84) | |
Working Capital |
(18.92) | (19.49) | (15.55) | (16.87) | |
Capital Expenditures |
— | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
(19.20) | (19.70) | (15.68) | (16.93) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
11.75 | 11.64 | 12.20 | 12.47 | |
Average Assets |
64.40 | 59.00 | 63.79 | 9.09 | |
Average Common Equity |
42.52 | 34.26 | 39.42 | (15.19) |
Columns are period end dates · fundamentals updated 2 Nov 2026